PDF(Pubmed)
Abstract：
UNASSIGNED: Male breast cancer (MBC) is a rare condition, and recent research has underscored notable distinctions between MBC and breast cancer in women. This study aimed to assess and contrast the long-term survival outcomes and disease patterns of MBC patients with those of their female counterparts.
UNASSIGNED: We analyzed data from 113,845 patients diagnosed with breast cancer who had undergone curative surgery from the Korean Breast Cancer Registry (KBCR) between January 1990 and August 2014 in Seoul, Korea. The five-year overall survival was analyzed according to clinicopathological characteristics.
UNASSIGNED: Among 113,845 patients with breast cancer, 473 MBC cases were included. The median duration of follow-up was 72 months. The median age at diagnosis was 60 and 48 years for MBC and female breast cancer, respectively. Most male patients (92.6%) underwent total mastectomy, while 50.4% of female patients underwent breast-conserving surgery. Among MBC, 63.2% received chemotherapy, and 83.9% of hormone receptor-positive male patients received endocrine therapy. In survival analysis, MBC demonstrated distinct 5-year overall survival patterns compared with female breast cancer, according to age at diagnosis. In women with breast cancer, the younger age group (≤40 years) demonstrated worse 5-year overall survival than did the older age group (>40 years) (91.3% vs 92.7%, p <0.05). While in MBC, the younger age group (≤40 years) demonstrated better 5-year overall survival than did the older age group (>40 years) (97.4% vs 86.4%, p <0.05).
UNASSIGNED: In conclusion within this extensive cohort, we have revealed unique survival patterns in MBC that diverge from those observed in women with breast cancer. This study enhances our comprehension of MBC prognosis and can potentially shed light on unresolved questions, paving the way for future research in the realm of MBC.
UNASSIGNED: We analyzed data from 113,845 patients diagnosed with breast cancer who had undergone curative surgery from the Korean Breast Cancer Registry (KBCR) between January 1990 and August 2014 in Seoul, Korea. The five-year overall survival was analyzed according to clinicopathological characteristics.
UNASSIGNED: Among 113,845 patients with breast cancer, 473 MBC cases were included. The median duration of follow-up was 72 months. The median age at diagnosis was 60 and 48 years for MBC and female breast cancer, respectively. Most male patients (92.6%) underwent total mastectomy, while 50.4% of female patients underwent breast-conserving surgery. Among MBC, 63.2% received chemotherapy, and 83.9% of hormone receptor-positive male patients received endocrine therapy. In survival analysis, MBC demonstrated distinct 5-year overall survival patterns compared with female breast cancer, according to age at diagnosis. In women with breast cancer, the younger age group (≤40 years) demonstrated worse 5-year overall survival than did the older age group (>40 years) (91.3% vs 92.7%, p <0.05). While in MBC, the younger age group (≤40 years) demonstrated better 5-year overall survival than did the older age group (>40 years) (97.4% vs 86.4%, p <0.05).
UNASSIGNED: In conclusion within this extensive cohort, we have revealed unique survival patterns in MBC that diverge from those observed in women with breast cancer. This study enhances our comprehension of MBC prognosis and can potentially shed light on unresolved questions, paving the way for future research in the realm of MBC.
摘要：
■男性乳腺癌（MBC）是一种罕见的疾病，最近的研究强调了女性MBC和乳腺癌之间的显著区别。这项研究旨在评估和对比MBC患者与女性患者的长期生存结果和疾病模式。
■我们分析了韩国乳腺癌登记处（KBCR）在1990年1月至2014年8月期间在首尔接受过治愈性手术的113,845例乳腺癌患者的数据。韩国。根据临床病理特征分析5年总生存期。
■在113,845例乳腺癌患者中，包括473例MBC病例。中位随访时间为72个月。MBC和女性乳腺癌的诊断中位年龄为60岁和48岁，分别。大多数男性患者（92.6％）接受了全乳房切除术，50.4%的女性患者接受了保乳手术。在MBC中,63.2%接受化疗,83.9%的激素受体阳性男性患者接受内分泌治疗.在生存分析中,与女性乳腺癌相比，MBC表现出明显的5年总体生存模式，根据诊断时的年龄。在患有乳腺癌的女性中，年轻年龄组（≤40岁）的5年总生存率低于老年组（>40岁）（91.3%vs92.7%，p<0.05)。在MBC,年轻年龄组（≤40岁）的5年总生存率优于老年组（>40岁）（97.4%vs86.4%，p<0.05)。
■在这个广泛的队列中，我们揭示了MBC独特的生存模式,与乳腺癌女性患者的生存模式不同.这项研究增强了我们对MBC预后的理解，并有可能揭示尚未解决的问题，为未来MBC领域的研究铺平了道路。
■我们分析了韩国乳腺癌登记处（KBCR）在1990年1月至2014年8月期间在首尔接受过治愈性手术的113,845例乳腺癌患者的数据。韩国。根据临床病理特征分析5年总生存期。
■在113,845例乳腺癌患者中，包括473例MBC病例。中位随访时间为72个月。MBC和女性乳腺癌的诊断中位年龄为60岁和48岁，分别。大多数男性患者（92.6％）接受了全乳房切除术，50.4%的女性患者接受了保乳手术。在MBC中,63.2%接受化疗,83.9%的激素受体阳性男性患者接受内分泌治疗.在生存分析中,与女性乳腺癌相比，MBC表现出明显的5年总体生存模式，根据诊断时的年龄。在患有乳腺癌的女性中，年轻年龄组（≤40岁）的5年总生存率低于老年组（>40岁）（91.3%vs92.7%，p<0.05)。在MBC,年轻年龄组（≤40岁）的5年总生存率优于老年组（>40岁）（97.4%vs86.4%，p<0.05)。
■在这个广泛的队列中，我们揭示了MBC独特的生存模式,与乳腺癌女性患者的生存模式不同.这项研究增强了我们对MBC预后的理解，并有可能揭示尚未解决的问题，为未来MBC领域的研究铺平了道路。
